WebApr 5, 2024 · The Isotonic Solutions and Major Adverse Renal Events Trial in Medicine (SMART-MED) and Surgical patients (SMART-SURG) studies sought to address this question in a pragmatic, unblinded, multiple-crossover trial of approximately 15,000 critically ill adults admitted to medical and surgical ICUs. Most patients were admitted through the ED (50% ... WebSep 19, 2024 · The Results. 15,802 patients were enrolled in the trial. Only a very small amount of fluid was used: about 1 litre in total during the entire ICU stay in both groups. About 5% of patients received both fluids because they were in the ICU during 2 different months. The primary composite outcome occurred in 14.3% of the balanced crystalloid …
IV fluid choice part 2: The SMART trial - First10EM
WebDesign, Setting, and Participants The SMART-CHOICE trial was an open-label, noninferiority, randomized study that was conducted in 33 hospitals in Korea and included 2993 patients undergoing PCI with drug-eluting stents. Enrollment began March 18, 2014, and follow-up was completed July 19, 2024. WebFeb 24, 2024 · The SMART Choice tool provides users with a prediction for improvement or deterioration / no change after surgery based on utility score change calculated from the Veterans-RAND 12 (VR-12) survey. ... The consequence of this practice may present as difficulty isolating the results of this trial to the SMART Choice tool. An additional … rcw conversion
SMART-CHOICE - American College of Cardiology
WebNov 1, 2024 · Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial … WebSep 30, 2024 · The SMART-CHOICE trial compared two antiplatelet strategies ― 3 months of DAPT followed by long-term P2Y12 inhibitor monotherapy (mainly with clopidogrel) or prolonged DAPT for 12 months or longer ― in 2993 patients who had undergone PCI with a drug-eluting stent. Results at 12 months showed a similar rate of ischemic events with … WebStudy design: The SMART-CHOICE trial is a prospective, open-label, multi-center, and randomized study designed to test the non-inferiority of P2Y12 inhibitor monotherapy … simulator is stopped